Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    IRLAB Therapeutics

    MCap

    SEK653m

    Last close

    SEK14.10

    ▲ 1.50 (11.90%)

    VolitionRx

    MCap

    USD51m

    Last close

    USD0.60

    ▲ 0.05 (9.82%)

    Portobello SpA

    MCap

    EUR12m

    Last close

    EUR2.38

    ▲ 0.20 (9.17%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Incannex Healthcare (NASDAQ: IXHL)

Last close As at 01/11/2024

USD0.97

▲ −0.11 (−10.19%)

Market capitalisation

62m

Latest Insights

View More

Healthcare | Update

Incannex Healthcare — Spotlight on Incannex’s progress in psychedelics

Healthcare | Flash note

Incannex Healthcare — On the road to psychotherapy clinics

Healthcare | Flash note

Incannex Healthcare — On to Phase II for IHL-675A

Healthcare | Flash note

Incannex Healthcare — A clinically active quarter
incannex07
Visit Website

Sector

Healthcare

Balance Sheet

Forecast net cash (A$m)

29.6

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (3.0) (36.3) (76.2)
Relative (12.3) (38.0) (79.3)
52 week high/low US$4.0/US$0.8

Financials

Incannex, an Australian-based biotech, has several active studies investigating cannabinoid combinations for a range of conditions, but is also focused on assessing psilocybin for the treatment of generalized anxiety disorder (GAD). In the psychedelics space, Incannex’s ongoing Phase II trial (Psi-GAD) received an encouraging interim review in March 2023, and we see the completion of the study in Q4 CY23 as a significant catalyst. Incannex has also recently announced developments in its psychedelic clinics business through its subsidiary Clarion Clinics Group. In this note, we provide an overview of psychedelics as therapeutics, the GAD market, and Incannex’s position in the emerging field of psychedelic-based therapies. Our valuation for Incannex stands at US$750.7m or US$11.83 per ADR (vs US$745.8m or US$11.75 per ADR previously).

Y/E Jun Revenue (A$m) EBITDA (A$m) PBT (A$m) EPS (fd) (c) P/E (x) P/CF (x)
2021A 2.0 N/A (8.2) (0.83) N/A N/A
2022A 0.8 N/A (14.9) (1.25) N/A N/A
2023E 0.1 N/A (20.7) (1.43) N/A N/A
2024E 0.1 N/A (33.4) (2.10) N/A N/A

Research

Flash note

Healthcare

Incannex Healthcare — On the road to psychotherapy clinics

Flash note

Healthcare

Incannex Healthcare — On to Phase II for IHL-675A

Healthcare

Update

Incannex Healthcare — Spotlight on Incannex’s progress in psychedelics
View All

Further insights

insight

Healthcare

Incannex’s US redomicile is now complete – what’s next?

insight

Healthcare

Incannex Healthcare: Is life better on Nasdaq?
Incannex mother and child

insight

Healthcare

Incannex Healthcare: Data opens path to treat anxiety

insight

Healthcare

Healthcare Week 2023
thumbnail_incannex

insight

Healthcare

Incannex Healthcare: Disrupting the obstructive sleep apnoea space with IHL-42X

insight

Healthcare

Seven things every investor needs to know about Incannex Healthcare

Thematics

thematic

Healthcare

Outlook for 2024: Life sciences – where has the conviction gone?

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare
volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

thematic

Healthcare

ASCO 2023 key takeaways
View All

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free